CA29668H7085 - Common Stock
ESSA PHARMA INC
NASDAQ:EPIX (5/17/2024, 7:00:02 PM)
After market: 5.98 +0.28 (+4.91%)5.7
-0.55 (-8.8%)
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The firm is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The firm is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
ESSA PHARMA INC
Suite 2600, 595 Burrard Street
Vancouver BRITISH COLUMBIA V5Z 1K5
P: 17783310962
CEO: David Parkinson
Employees: 50
Website: https://www.essapharma.com/
EPIX stock results show that ESSA Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...
/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...
/PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for...
Here you can normally see the latest stock twits on EPIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: